
Biotech
Exponential advances in the ability to read, write, and manipulate DNA, together with high throughput automation and ML/AI, are transforming biology from a science to a true engineering discipline. We can now measure biological systems with greater precision, model them with greater efficacy, and make targeted interventions in a patient’s health with greater probability of success.
Our primary investment scope includes pre-seed and seed-stage biotechnology companies developing platforms and products across therapeutics, diagnostics, and life sciences tools, software, and services. We have been partnering with biotech founders since our very first fund, and our biotech portfolio now includes two public companies.
Pear perspectives
Here are some of the things we’re interested in, but there are far more than what we’ve shared on this page. If you’re building something cool, we want to hear from you, regardless of whether it’s listed here or not.
Next-generation therapeutic modalities
Emerging therapeutic modalities, such as genomic medicines (including gene therapy, RNA therapeutics, and gene editing), cell therapies, targeted protein degraders, and antibody-drug conjugates, have enabled more precise and effective treatments for a range of diseases and have expanded the universe of druggable targets. We are interested in technologies that can dramatically improve the efficacy, safety, and reach of these modalities.
Precision medicine
The use of biomarkers for patient selection has significantly bolstered the likelihood of successful translation for drug programs in oncology and have enabled therapeutic product profiles with better efficacy and safety. We are excited about the broader integration of biomarker-guided drug development strategies, not only within oncology but also across diverse therapeutic areas.
Lead Partners
Advisory Council
-
Sasan Amini
Co-Founder & CEO, Clear Labs
-
Nazil Azimi
Biotech Executive, Board member at Omeat
-
Helmy Eltoukhy
Co-Founder and CEO of Guardant Health (Pear Company)
-
Kristen Fortney
CEO and Co-Founder of BioAge (Pear Company)
-
Hani Goodarzi
Associate Professor, Department of Biophysics & Biochemistry, UCSF
-
Curt Herberts
President & COO, Kriya Therapeutics
-
Martin Madaus
Fmr. CEO of Ortho Clinical Diagnostics, Fmr. CEO of Millipore
-
Angele Maki
Seasoned BioPharma BD Leader
-
James Mutamba
CBO, Arrakis Therapeutics
-
Reza Oliyai
Fmr. SVP of Pharmaceutical and Biologics Operations at Gilead
-
Armon Sharei
Fmr. Co-Founder and CEO, SQZ Biotech
-
Roxana Daneshjou
MD, Assistant Professor of Biomedical Data Science and Dermatology at Stanford School of Medicine
-
Daniel Simon
CBO, Revolution Medicines
-
Stan Skrzypczak
Founder, 5 Prime Life Science Consulting, Inc.
-
James Zou
Assistant Professor of Biomedical Data Science, Stanford